A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 144
Summary
- Conditions
- Endometrial Carcinoma
- Advanced Solid Tumors
- Small Cell Lung Cancer
- Breast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 Negative
- Cervical Carcinoma
- Colorectal Carcinoma
- Gastric or Gastroesophageal Junction Adenocarcinoma
- Urothelial Carcinoma
- Hepatocellular Carcinoma
- Melanoma (Excluding Uveal Melanoma)
- Undifferentiated Pleomorphic Sarcoma
- Nasopharyngeal Carcinoma
- Non Small Cell Lung Carcinoma
- Squamous Cell Carcinoma of the Head and Neck
- Pancreatic Carcinoma
- Renal Cell Carcinoma
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: RandomizedIntervention Model: Sequential AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03752398
- Collaborators
- ICON plc
- Investigators
- Study Director: David Liebowitz, MD Xencor, Inc.